Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-REX: Ranibizumab Monthly vs Treat & Extend in Wet AMD
NCT01748292Phase 3Completed
- Sponsor
- Charles C. Wykoff
- Start
- Dec 2012
- Primary completion
- Feb 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Charles C. Wykoff. Primary endpoint: Mean Change in BCVA by ETDRS Letter Score From Baseline at 36 months. Started Dec 2012; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01748292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01748292.